G2GBIO
Clinical-Stage Biotech Company
Targeting Global Markets with Prime Quality Microsphere Injectables

G2GBIO Good to the Globe Biotech Company

For eight years since its inception in March 2017, G2GBIO has applied for 171 patents, including 38 domestic, applications for 110 overseas individual countries and 23 PCT. To date, 65 applications were registered, including 44 international and 21 domestic patents, with the rest being pending or under review.

  • Innovative Long-Acting Microsphere Platform (InnoLAMP): Drug Development and Manufacturing Technology
    InnoLAMP uses biodegradable polymers to create cutting-edge injectable microspheres. Our technology ensures precise drug delivery and prolonged body-wise activity, all while being cost-effective and highly sustainable, promising particularly effective commercialization processes.
  • Application of InnoLAMP Technology
    InnoLAMP technology enhances drug sustainability, perfect for chronic disease management and simplifying administration. As lifespans increase, our technology offers crucial convenience for elderly and chronically ill patients, while also reducing the side effects associated with long-term drug use.
  • InnoLAMP Patents
    G2GBIO's patented InnoLAMP technology excels in mass-producing uniform microsphere drug injectables with sustained release and high reproducibility. Suitable for peptides, small molecules, and various indications, it offers a cost-effective solution to meet global demand for high-quality, sustained-release drugs. We are committed to meeting global demand for cost-effective, sustained-release drug solutions with unparalleled quality and efficiency.
  • Innovative Drug Delivery Systems for Advanced Therapeutics
    G2GBIO has achieved preclinical drug release profiles for its target product (e.g. GB-5001) and consistent Phase 1 clinical trial results, which proved that our advanced technology minimizes injection site pain and enhances bioavailability, distinguishing our microsphere injectables from the competition.
  • Diverse Drug Pipeline
    G2GBio’s R&D pipeline focuses on treatments for Alzheimer’s, Type 2 diabetes, post-operative pain, Schizophrenia with several drugs already in clinical trials or preparation for clinical studies. Through strategic partnerships with global pharmaceutical companies, we plan to significantly expand our pipeline, leveraging InnoLAMP technology for future drug development.
  • Emphasis on R&D
    In May 2022, G2GBIO completed its 4,177㎡ research center in Osong BioValley, featuring a larger scale facility. Led by a team of experts, including the CEO with deep expertise in sustained-release technology also actively engaged in research and development. Due to their dedication, G2GBIO has quickly achieved significant R&D milestones. Moving forward, we remain committed to prioritizing R&D as the key to our mission: delivering quality medicines to improve lives worldwide.
  • Strategic Partnerships and Licensing Agreements
    G2GBIO’s dynamic R&D progress has secured several significant joint development and licensing agreements. We’re partnering with Korea Pharma and Humedix on sustained-release injectables for Alzheimer’s Disease, with Hanwha Pharma on hepatitis B sustained-release injectables, and with Keyfron Bio on veterinary medicines. We are also exploring further strategic partnerships for other pipeline drugs. G2GBIO remains committed to pursuing these collaborations drive sustainable growth and innovation.

CEO'S MESSAGE

G2GBIO, a company founded with the entrepreneurial spirit of Human First Respect for Life by Providing Good Medicines

As the global aging population continues to grow, the prevalence of chronic diseases like dementia, diabetes, and arthritis increases, driving demand for Long-Acting Injectables (LAIs) that enhance medication convenience and adherence.

LAIs are emerging as a key solution for managing these conditions, offering benefits such as improved patient compliance and reduced treatment costs.

LAIs not only align with the goals of healthy aging but also provide significant financial advantages compared to developing new drugs from scratch, costing roughly one-tenth as much and taking less than half the time.

Despite these benefits, commercial production of sustained-release pharmaceuticals faces high entry barriers.

G2GBIO is addressing this challenge by advancing treatments for chronic diseases through our proprietary InnoLAMP (Innovative Long-Acting Microsphere Platform) technology.

We are very proud that our unique approach ensures the production of high-quality, uniform microsphere injectables on a commercial scale.

With InnoLAMP, G2GBIO is well-positioned to expand globally and continuously innovate, aiming to bring new, effective drugs to the market.

We are committed to driving progress and enhancing patient care worldwide.

Thank you.

Heeyong Lee

Leadership

Heeyong Lee CEO
  • BS in Biochemistry from Yonsei Univ., PhD in Biotechnology, KAIST, & Post doctor in Univ. of Kentucky
  • 27 years’ experience in SR drug delivery
  • Participated in the development of SR prostate cancer treatment drug submitted to US FDA ANDA
  • Research and Business Development at Peptron
  • Licensing & technology transfer to Daewoong Pharmaceutical, Yuhan and AZAD (Switzerland)
  • Commercialization of prostate cancer treatment drugs
  • Commercial experience for long-acting microsphere
Eunyoung Seol Head of R&D
  • B.S/M.S in Biochemistry from Chungnam National Univ.
  • 23 years’ experience in SR drug delivery
  • Formerly responsible for the development of sustained-release injections at Daewoong Pharmaceuticals, Dong Kuk Pharm, and Peptron
Mark Tracy, Ph.D. President of Tracy BioConsulting
  • President: Tracy BioConsulting, LLC
  • Former Role: Senior Director at Alnylam, Inc.
  • Former President: Controlled Release Society
  • Former Director: Alkermes, Inc.
Taher Darreh-Shori Ph.D Principal Researcher of Karolinska Institutes
  • Member: EPN / Regionala Etikprovningsnamnden
  • Deputy Head: Division of Translational Alzheimer Neurobiology, Karolinska Institutet
  • Pharmacist: Apoteket AB

HISTORY

2017-Present

2026
May-
Registered U.S. patent for semaglutide
Jan-
Registered formulation patent for GB-5021 (schizophrenia treatment)
2025
Aug-
Listed on KOSDAQ (IPO)
Jul-
Selected for the Ministry of Trade, Industry and Energy's long-acting immunosuppressant formulation development project
Jun-
Filed patent for microsphere process improvement
Mar-
Filed formulation patent for GB-5021 (schizophrenia treatment)
2024
Aug-
Passed the Technology Evaluation for KOSDAQ Technology Special Listing
Jul-
Signed an MOU for CDMO Services of Long-Acting Injectable Drugs Received Approval for Phase 1 Clinical Trial Plan for Alzheimer’s Treatment in Korea
Apr-
elected for the Ministry of SMEs and Startups Project for Formulation Development and Technology Commercialization of Long-Acting Schizophrenia Treatments
Jan-
Submitted IND Application for Phase 2 Clinical Trial of GB-2006 (Postoperative Pain Relief for Animals) in Korea
2023
Dec-
Attracted Pre-IPO Investment
Completed Phase 1 Clinical Trial for GB-5001 (Alzheimer's Disease Medication) in Canada
Nov-
Initiated Phase 1 Clinical Trial for GB-5001 in Korea
Oct-
Received the Minister's Award from the Ministry of SMEs and Startups (MSS) in the Small Business Technology Innovation Competition
Initiated Phase 1 Clinical Trial for GB-6002 (Postoperative Pain Medicine) in Korea
Phase 1 Clinical Trial Plan Approved by the Ministry of Food and Grug Safety (MFDS) for GB-5001
Sep-
IND Application Approved by the MFDS for Phase 1 Clinical Trial with GB-6002
Mar-
IND Application Approved by the MFDS for Phase 1 Clinical Trial with GB-5001
2022
Dec-
Attracted Series C investments (a total of 14.6 billion won)
Oct-
Selected for the Korea-UK international joint technology development project selected
Contracted Domestic Licensing with Humedix and Koreapharma for the Alzheimer's Disease Long-Acting Injectables 08
Aug-
Initiated Phase 1 Clinical Trial for a Long-Acting Alzheimer's Disease Drug in Canada
Jul-
Selected as a Co-Research Institute for the MSS’ Industry-Academy Platform Technology Development Project
Jun-
Participated in the MFDS Research to Establish a Synthetic Peptide Drug Evaluation System
May-
Established a New R&D Center in Osong
Mar-
Agreed upon Collaboration with Hanwha for HBV Development
Jan-
Participated in the MSS' Innovation Sector Startup Package (BIG3) Project
2021
Oct-
MOU with Humedix on the development of sustained-release injectable GB-5001 Canada Phase 1 clinical trial approved
Aug-
MOU with Samyang Holdings on the development of sustained-release injectable
Jul-
Selected by the MOHW for an R&D Project Linked to Healthcare and Medical Investment Infrastructure (Government Project)
May-
Agreed with Keyfron Bio (Biotoxtech Subsidiary) upon Joint Development for Veterinary Medicines
Feb-
Attracted Bridge Investments from the SI, FI, and KIBO the Government Agency (a total of 2 billion won)
2020
Jul-
Selected by the MSS for the Start-up Growth Support in the Innovative Field (BIG3, Government project)
Jun-
Attracted Series B Investments from seven institutes (a total of 11.4 billion won)
Jan-
Establishment of the GMP facility
2019
Jul-
Agreed with Chungnam National University Hospital for Regional Hub Innovative Physician-Scientist Collaborative Research
Jun-
Selected by the MSS for a Preliminary Industry-Academia-Research Collaboration Project
2018
Apr-
Selected by the MOHW for Domestic KDRC (Government project)
Selected by the MOTIE for a Promising Bio IP Project (Government project)
Attracted Series A Investments (a total of 8 billion won) from 6 Institutes
2017
Dec-
Selected for a High-Tech Medical Complex Base Technology Construction Project
Jul-
Selected by the SMBA for K-startup
Mar-
Established G2G Bio Co., Ltd.

Office Building

G2GBIO completed the construction of a new office building in Osong in May 2022, designed to offer an exceptional working environment for our team. The facility includes state-of-the-art research and development facilities to support our innovative projects

Organizational Diagram

G2GBIO will maintain sustainable management driven by the principles of TOP STARS*
(*TO= together ; P= precision ; S= speed ; T= trust ; A= active ; R= responsibility ; S= self-development)

ADDRESS

Head Office
Address
  21, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si,   Chungcheongbuk-do S.Korea
Phone
  (+82) 043.270.6000
Email
  contactus@g2gbio.com
Office (Seoul)
Address
  Room 401, Plaza 654 Building, 551 Eonju-ro, Gangnam-gu, Seoul S.Korea
Phone
  (+82) 043.270.6000
Email
  contactus@g2gbio.com
GMP facility
Address
  123, Osongsaengmyeong-ro, Osong-eup, Heungdeok-gu, Cheongju-si,    Chungcheongbuk-do S.Korea
Phone
  (+82) 043.270.6059
Email
  contactus@g2gbio.com